Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | JAK3 Q988P |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
JAK3 Q988P | hematologic cancer | sensitive | LGH447 | Preclinical - Cell culture | Actionable | In a preclinical study, LGH447 inhibited viability and proliferation of transformed cells expressing JAK3 Q988P in culture (PMID: 39033228). | 39033228 | |
JAK3 Q988P | hematologic cancer | decreased response | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing JAK3 Q988P were less sensitive to Jakafi (ruxolitinib) treatment compared to cells expressing JAK3 M511I in culture (PMID: 37712558). | 37712558 | |
JAK3 Q988P | hematologic cancer | sensitive | Tofacitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Xeljanz (tofacitinib) inhibited growth of transformed cells expressing JAK3 Q988P in culture (PMID: 37712558). | 37712558 |